Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry|August 25, 2021
Virtual screening and biological evaluation of PPARγ antagonists as potential anti-prostate cancer agentsSuliman Almahmoud, Catherine C Elix, Jeremy O Jones, et al.
ACS Chemical Biology|December 21, 2013
Ligand-independent and tissue-selective androgen receptor inhibition by pyrviniumMinyoung Lim, Maya Otto-Duessel, Miaoling He, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|September 8, 2012
Effects of parabens on adipocyte differentiationPan Hu, Xin Chen, Rick J Whitener, et al.
Urologic Oncology|January 1, 2018
Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamideSumanta K Pal, Miaoling He, Lin Chen, et al.
Plos One|July 22, 2015
Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer ModelMengmeng Liang, Helty Adisetiyo, Xiuqing Li, et al.
Urologic Oncology|May 22, 2012
Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysisSumanta K Pal, Jeremy O Jones, Courtney Carmichael, et al.
ACS Omega|March 16, 2019
Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain Inhibitor PyrviniumSumanta K Pal, Ben Yi Tew, Minyoung Lim, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 14, 2009
Non-competitive androgen receptor inhibition in vitro and in vivoJeremy O Jones, Eric C Bolton, Yong Huang, et al.
Urologic Oncology|November 28, 2016
Vitamin K epoxide reductase expression and prostate cancer riskBen Yi Tew, Sumanta K Pal, Miaoling He, et al.
ACS Medicinal Chemistry Letters|July 16, 2025
Identification of a Novel Indolizine RORγT Inverse Agonist Using the AI-Driven Drug Design PlatformRafał A Bachorz, Joanna Pastwińska, Michael S Lawless, et al.
Pageof 5